These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 9166950)

  • 1. The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group.
    Sawka C; Olivotto I; Coldman A; Goel V; Holowaty E; Hislop TG
    Br J Cancer; 1997; 75(10):1534-42. PubMed ID: 9166950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of initial management of node-negative breast cancer in two Canadian provinces. British Columbia/Ontario Working Group.
    Goel V; Olivotto I; Hislop TG; Sawka C; Coldman A; Holowaty EJ
    CMAJ; 1997 Jan; 156(1):25-35. PubMed ID: 9006561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance with practice guidelines for node-negative breast cancer.
    Olivotto A; Coldman AJ; Hislop TG; Trevisan CH; Kula J; Goel V; Sawka C
    J Clin Oncol; 1997 Jan; 15(1):216-22. PubMed ID: 8996145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant systemic therapy and survival after breast cancer.
    Olivotto IA; Bajdik CD; Plenderleith IH; Coppin CM; Gelmon KA; Jackson SM; Ragaz J; Wilson KS; Worth A
    N Engl J Med; 1994 Mar; 330(12):805-10. PubMed ID: 8114832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary care physician use across the breast cancer care continuum: CanIMPACT study using Canadian administrative data.
    Jiang L; Lofters A; Moineddin R; Decker K; Groome P; Kendell C; Krzyzanowska M; Li D; McBride ML; Mittmann N; Porter G; Turner D; Urquhart R; Winget M; Zhang Y; Grunfeld E
    Can Fam Physician; 2016 Oct; 62(10):e589-e598. PubMed ID: 27737994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study.
    McBride ML; Groome PA; Decker K; Kendell C; Jiang L; Whitehead M; Li D; Grunfeld E;
    BMC Cancer; 2019 Jul; 19(1):659. PubMed ID: 31272420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case selection and appropriateness of coronary angiography and coronary artery bypass graft surgery in British Columbia and Ontario.
    Anderson GM; Pinfold SP; Hux JE; Naylor CD
    Can J Cardiol; 1997 Mar; 13(3):246-52. PubMed ID: 9117912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Kunkler I
    J Natl Cancer Inst; 2005 Aug; 97(15):1162-3; author reply 1163-4. PubMed ID: 16077078
    [No Abstract]   [Full Text] [Related]  

  • 11. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection.
    Dees EC; Shulman LN; Souba WW; Smith BL
    Ann Surg; 1997 Sep; 226(3):279-86; discussion 286-7. PubMed ID: 9339934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in breast cancer diagnosis for immigrant women in Ontario and BC: results from the CanIMPACT study.
    Lofters AK; McBride ML; Li D; Whitehead M; Moineddin R; Jiang L; Grunfeld E; Groome PA;
    BMC Cancer; 2019 Jan; 19(1):42. PubMed ID: 30626375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice patterns of lymph-node mapping and sentinel-node biopsy for breast cancer in British Columbia.
    Chua B; Olivotto IA; Donald JC; Hayashi AH; Davis N; Rusnak CH
    Can J Surg; 2003 Aug; 46(4):273-8. PubMed ID: 12930104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients.
    Ozen M; Gunduz M; Ates O; Babacan T; Sever AR; Akin S; Ozisik Y; Altundag K
    J BUON; 2016; 21(4):799-808. PubMed ID: 27685899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
    Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
    J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy in breast cancer.
    Robert NJ
    Obstet Gynecol Clin North Am; 1994 Dec; 21(4):693-707. PubMed ID: 7731642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
    Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.